The Rgr oncogene induces tumorigenesis in transgenic mice

Cancer Research

Volumn 64, Issue 17, 2004, Pages 6041-6049

  Jiménez, María ^a,b   Pérez De Castro, Ignacio ^a,b   Benet, Marta ^a   García, Juan F ^b   Inghirami, Giorgio ^a,c   Pellicer, Angel ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2B; PROTEIN P15; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; EMBRYO; FIBROSARCOMA; GENE EXPRESSION; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RGR ONCOGENE; THYMOCYTE; THYMUS LYMPHOMA; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIGENS, CD4; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DISEASE PROGRESSION; FEMALE; LYMPHOMA, T-CELL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NIH 3T3 CELLS; RAL GUANINE NUCLEOTIDE EXCHANGE FACTOR; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 4344642864     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3389     Document Type: Article

References (49)

1. D'Adamo DR, Novick S, Kahn JM, Leonardi P, Pellicer A. rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral. Oncogene 1997;14:1295-305.
2. White MA, Vale T, Camonis JH, Schaefer E, Wigler MH. A role for the Ral guanine nucleotide dissociation stimulator in mediating Ras-induced transformation. J Biol Chem 1996;271:16439-42.
3. Hernandez-Munoz I, Malumbres M, Leonardi P, Pellicer A. The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways, Oncogene 2000;19:2745-57.
4. INK4b. Mol Cell Biol 2000;20:2915-25.
5. Perez de Castro IP, Malumbres M, Santos J, Pellicer A, Femandez-Piqueras J. Cooperative alterations of Rb pathway regulators in mouse primary T cell lymphomas. Carcinogenesis (Lond) 1999;20:1675-82.
6. Hernandez-Munoz I, Benet M, Calero M, et al. rgr oncogene: activation by elimination of translational controls and mislocalization. Cancer Res 2003;63: 4188-95.
7. Leonardi P, Kassin E, Hernandez-Munoz I, et al. Human rgr: transforming activity and alteration in T-cell malignancies. Oncogene 2002;21:5108-16.
8. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. "Green mice" as a source of ubiquitous green cells. FEBS Lett 1997;407:313-9.
9. Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M. Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol 1989; 9:24-33.
10. Sawada S, Scarborough JD, Killeen N, Littman DR. A lineage-specific transcriptional silencer regulates CD4 gene expression during T lymphocyte development. Cell 1994;77:917-29.
11. Wigler M, Pellicer A, Silverstein S, Axel R. Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor. Cell 1978;14:725-31.
12. Gordon JW, Scangos GA, Plotkin DJ, Barbosa JA, Ruddle FH. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc Natl Acad Sci USA 1980;77:7380-4.
13. Gordon JW, Ruddle FH. Gene transfer into mouse embryos: production of transgenic mice by pronuclear injection. Methods Enzymol 1983;101:411-33.
14. Taketo M, Schroeder AC, Mobraaten LE, et al. FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci USA 1991;88:2065-9.
15. Malumbres M, Mangues R, Ferrer N, Lu S, Pellicer A. Isolation of high molecular weight DNA for reliable genotyping of transgenic mice. Biotechniques 1997;22: 1114-9.
16. Theuring F, Gotz W, Balling R, et al. Tumorigenesis and eye abnormalities in transgenic mice expressing MSV-SV40 large T-antigen. Oncogene 1990;5:225-32.
17. Khillan JS, Oskarsson MK, Propst F, et al. Defects in lens fiber differentiation are linked to c-mos overexpression in transgenic mice. Genes Dev 1987;1:1327-35.
18. Gotz W, Theuring F, Favor J, Herken R. Eye pathology in transgenic mice carrying a MSV-SV 40 large T-construct. Exp Eye Res 1991;52:41-9.
19. Sutrave P, Copeland TD, Showalter SD, Hughes SH. Characterization of chicken c-ski oncogene products expressed by retrovirus vectors. Mol Cell Biol 1990;10: 3137-44.
20. DeMayo FJ, Damak S, Hansen TN, Bullock DW. Expression and regulation of the rabbit uteroglobin gene in transgenic mice. Mol Endocrinol 1991;5:311-8.
21. Sandmoller A, Voss AK, Hahn J, et al. Cell-specific, developmentally and hormonally regulated expression of the rabbit uteroglobin transgene and the endogenous mouse uteroglobin gene in transgenic mice. Mech Dev 1991;34:57-67.
22. Gomez Lahoz E, Lopez de Haro MS, Esponda P, Nieto A. Tissue-specific and hormonally regulated expression of the puromycin N-acetyltransferase-encoding gene under control of the rabbit uteroglobin promoter in transgenic mice. Gene (Amst) 1992;117:255-8.
23. Margraf LR, Finegold MJ, Stanley LA, et al. Cloning and tissue-specific expression of the cDNA for the mouse Clara cell 10 kD protein: comparison of endogenous expression to rabbit uteroglobin promoter-driven transgene expression. Am J Respir Cell Mol Biol 1993;9:231-8.
24. INK4c cell cycle inhibitors in proliferation and tumorigenesis. EMBO J 2000;19: 3496-506.
25. Zhu K, Debreceni B, Bi F, Zheng Y. Oligomerization of DH domain is essential for Dbl-induced transformation. Mol Cell Biol 2001;21:425-37.
26. Katzav S, Martin-Zanca D, Barbacid M. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J 1989;8:2283-90.
27. Dupuy AJ, Morgan K, von Lintig FC, et al. Activation of the Rap1 guanine nucleotide exchange gene, CalDAG-GEF I, in BXH-2 murine myeloid leukemia. J Biol Chem 2001;276:11804-11.
28. Urano T, Emkey R, Feig LA. Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. EMBO J 1996;15:810-6.
29. Hamad NM, Elconin JH, Karnoub AE, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 2002;16:2045-57.
30. Ward Y, Wang W, Woodhouse E, et al. Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways. Mol Cell Biol 2001; 21:5958-69.
31. Gildea JJ, Harding MA, Seraj MJ, Gulding KM, Theodorescu D. The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Res 2002;62: 982-5.
32. Henry DO, Moskalenko SA, Kaur KJ, et al. Ral GTPases contribute to regulation of cyclin D1 through activation of NF-kappaB. Mol Cell Biol 2000;20:8084-92.
33. Lee T, Feig L, Montell DJ. Two distinct roles for Ras in a developmentally regulated cell migration. Development (Camb) 1996;122:409-18.
34. Suzuki J, Yamazaki Y, Li G, Kaziro Y, Koide H. Involvement of Ras and Ral in chemotactic migration of skeletal myoblasts. Mol Cell Biol 2000;20:4658-65. Erratum in: Mol Cell Biol 2000;20:7049.
35. Suzuki J, Yamazaki Y, Li G, Kaziro Y, Koide H. Involvement of Ras and Ral in chemotactic migration of skeletal myoblasts. Mol Cell Biol 2000;20:4658-65. Erratum in: Mol Cell Biol 2000;20:7049.
36. Stone S, Dayananth P, Jiang P, et al. Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene 1995;11:987-91.
37. Glendening JM, Flores JF, Walker GJ, et al. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res 1995;55:5531-5.
38. Malumbres M, Perez de Castro I, Santos J, et al. Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas. Oncogene 1997;14: 1361-70.
39. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996;56:722-7.
40. Herman JG, Civin CI, Issa JP, et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997;57:837-41.
41. Batova A, Diccianni MB, Yu JC, et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 1997;57:832-6.
42. Malumbres M, Perez de Castro I, Santos J, Fernandez Piqueras J, Pellicer A. Hypermethylation of the cell cycle inhibitor p15INK4b 3′-untranslated region interferes with its transcriptional regulation in primary lymphomas. Oncogene 1999;18: 385-96.
43. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8: 23-6.
44. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-77.
45. Mangues R, Symmans WF, Lu S, Schwartz S, Pellicer A. Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis. Oncogene 1996;13:1053-63.
46. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 2002;39:527-79.
47. Pals ST, Drillenburg P. CD44 expression predicts disease outcome in localized large B cell lymphoma. Blood 2000;95:1900-10.
48. Downing JR, Shurtleff SA, Zielenska M, et al. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase- polymerase chain reaction. Blood 1995;85:3416-22.
49. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003;3:685-94.